Lv1
90 积分 2021-09-13 加入
Measurable residual disease in hematologic malignancies: a biomarker in search of a standard
3天前
已完结
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
3天前
已完结
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
3天前
已完结
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
11天前
已完结
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
16天前
已完结
[Expert consensus on molecular pathology testing of soft tissue and bone tumor (2022 version)]
1个月前
已完结
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
1个月前
已完结
B-cell non-Hodgkin lymphomas
1个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
1个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
1个月前
已完结
皖公网安备34019202002308
